Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Perphenazine
Drug ID BADD_D01743
Description An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
Indications and Usage For use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.
Marketing Status approved
ATC Code N05AB03
DrugBank ID DB00850
KEGG ID D00503
MeSH ID D010546
PubChem ID 4748
TTD Drug ID D02HED
NDC Product Code 42973-165; 51407-697; 68084-607; 68382-592; 0781-8049; 23155-800; 23155-802; 51407-694; 70518-0710; 70518-2639; 70518-3106; 0904-6599; 63629-2248; 63629-2249; 63629-2250; 70518-0940; 70518-2985; 70518-3257; 70771-1042; 64980-290; 70518-0458; 70518-0731; 70518-1739; 70518-3108; 0591-4103; 0781-8047; 52536-164; 64980-291; 64980-292; 64980-293; 68382-593; 70518-1125; 71205-842; 0591-4102; 0603-5060; 0603-5061; 0904-6600; 52536-168; 63629-2251; 63629-2253; 70518-3121; 71205-843; 23155-801; 52536-162; 52536-170; 68084-602; 70771-1041; 71205-844; 0591-4101; 23155-799; 53808-1124; 70518-3033; 0904-6601; 46204-0003; 51407-696; 63629-2252; 68382-591; 70771-1044; 71205-841; 0603-5062; 0603-5063; 0781-8046; 0781-8048; 0591-4104; 68382-594; 70518-2890; 70771-1043; 65372-1191; 51407-695
UNII FTA7XXY4EZ
Synonyms Perphenazine | Perfenazine | Chlorpiprazine | Trilafon
Chemical Information
Molecular Formula C21H26ClN3OS
CAS Registry Number 58-39-9
SMILES C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Suicidal ideation19.12.01.003--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Tachycardia02.03.02.007--Not Available
Tardive dyskinesia17.01.02.012--Not Available
Throat tightness22.12.03.031; 19.01.02.005--Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.003--Not Available
Tongue discolouration07.14.02.006--Not Available
Tongue disorder07.14.01.002--Not Available
Tongue oedema07.14.02.007; 23.04.01.009; 10.01.05.008--Not Available
Tongue spasm07.14.02.008--Not Available
Torticollis17.01.03.003; 15.05.04.003--Not Available
Tremor17.01.06.002--
Trismus15.05.04.004; 17.01.03.004--
Urinary retention20.02.02.011--
Urticaria23.04.02.001; 10.01.06.001--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Brain oedema17.07.02.003; 12.01.10.010--
Muscle tightness15.05.03.007--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.001--Not Available
Faecaloma07.01.03.004--Not Available
Faecalith07.01.03.007--Not Available
Urine output increased13.13.03.002--Not Available
Libido disorder19.08.03.004; 21.03.02.006--Not Available
Lactation disorder18.06.02.003; 21.05.02.004--
Decreased appetite14.03.01.005; 08.01.09.028--
Blood disorder01.05.01.004--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages